Workup for a Rectal Mass
For any newly identified rectal mass, perform digital rectal examination (DRE) and rigid sigmoidoscopy to measure distance from the anal verge, followed by endoscopy with biopsy for histopathological confirmation, then proceed with high-resolution pelvic MRI for locoregional staging and CT chest/abdomen/pelvis for distant metastases 1, 2.
Initial Diagnostic Steps
Clinical Assessment
- Digital rectal examination (DRE): Essential first step to assess tumor location, mobility, and relationship to anal sphincter 1
- Rigid sigmoidoscopy: Measure exact distance from anal verge (more accurate than flexible endoscopy) 1
- Tumors ≤15 cm from anal margin = rectal cancer
15 cm = colon cancer (managed differently)
- Categorize as: Low (0-5 cm), Middle (>5-10 cm), or High (>10-15 cm) rectal 1
Tissue Diagnosis
- Colonoscopy with biopsy: Obtain histopathological confirmation 1
- Complete colonoscopy to cecum: Rule out synchronous lesions 1
Critical caveat: For large laterally spreading lesions or advanced rectal lesions where endoscopic resection is considered, avoid routine biopsy as it causes fibrosis that complicates subsequent endoscopic treatment 3
Staging Workup
Locoregional Staging (T and N stage)
High-resolution pelvic MRI is the gold standard for local staging 1, 2, 4. The American College of Surgeons Commission on Cancer requires separate local and distant staging with MRI and CT respectively 2.
MRI Protocol Details 4:
- High-resolution T2-weighted sequences in three planes
- Small field of view focused on rectum
- Thin slices (3 mm or less)
- Use sigmoid take-off as landmark to distinguish rectal from sigmoid cancer
- Assess:
- T stage: Depth of tumor invasion through bowel wall layers
- Mesorectal fascia (MRF) involvement: Distance ≤1 mm = involved (high-risk feature)
- Extramural vascular invasion (EMVI): Predicts worse outcomes
- Nodal status: Use patient-level approach; lateral pelvic nodes ≥7 mm are suspicious
- Relationship to anal sphincter complex
- Extramural depth of invasion: >5 mm = high-risk
Alternative/Adjunct for Early Lesions:
- Endorectal ultrasound (ERUS): Acceptable for early-stage tumors (T1-T2) to assess depth of invasion 1, 5
- Better for superficial lesions than MRI
- Cannot assess mesorectal fascia or lateral nodes as well as MRI
CT has poor accuracy (50-70%) for local T and N staging and should NOT be used as primary locoregional staging modality 2.
Distant Metastasis Staging (M stage)
CT chest, abdomen, and pelvis with IV contrast 1, 2:
- Standard for detecting distant metastases
- Evaluate liver, lungs, peritoneum, distant lymph nodes
- CT is superior to MRI for M staging
PET-CT: Reserved for specific scenarios 1:
- Extensive EMVI on MRI (to detect occult distant disease)
- Equivocal findings on conventional imaging
- NOT routine for all patients
Additional Assessments
For patients >70 years: Formal geriatric assessment or frailty screening before treatment planning, as age/comorbidity increases postoperative mortality and treatment toxicity 1
Tumor markers: Baseline CEA (carcinoembryonic antigen) for surveillance purposes 1
Multidisciplinary Team Discussion
All patients must be discussed at specialized MDT meeting before treatment 1:
- Named radiologists, surgeons, radiation oncologists, medical oncologists, pathologists
- Review imaging, pathology, patient factors
- Determine treatment pathway based on risk stratification
Risk Stratification Based on Imaging
Low-Risk (Early Stage)
Intermediate-Risk
- T3 (early), N0
- No MRF involvement, no EMVI
- Treatment: May proceed to surgery or selective neoadjuvant therapy 1
High-Risk (Locally Advanced)
- T3 (advanced) or T4
- N+ disease
- MRF involvement (≤1 mm)
- EMVI present
- Extramural invasion >5 mm
- Treatment: Total neoadjuvant therapy (TNT) before surgery 2, 6
Key Pitfalls to Avoid
Do NOT rely on CT for locoregional staging - it misses critical details about MRF involvement and understages T2/early T3 lesions 2
Do NOT use lymph node size alone to determine N stage - nodes <5 mm can harbor metastases; morphology matters more than size 2
Do NOT biopsy large benign-appearing lesions if endoscopic resection is planned - causes fibrosis 3
Do NOT forget to distinguish upper rectal (>12 cm) from mid/low rectal - upper rectal cancers are treated as colon cancer without neoadjuvant radiotherapy 1
Consider benign mimics in young patients - colitis cystica profunda, GI stromal tumors, lymphoma, and other rare entities can mimic rectal cancer endoscopically and radiologically 7, 8
Summary Algorithm
- DRE + rigid sigmoidoscopy → measure distance from anal verge
- Colonoscopy with biopsy → confirm adenocarcinoma, exclude synchronous lesions
- High-resolution pelvic MRI → locoregional T/N staging, assess high-risk features
- CT chest/abdomen/pelvis with contrast → distant metastases
- MDT discussion → risk stratification and treatment planning
- Selective ERUS for early superficial lesions if considering local excision
- Selective PET-CT only if extensive EMVI or equivocal findings
This standardized approach ensures accurate staging to guide appropriate treatment selection - whether immediate surgery for early-stage disease, neoadjuvant therapy for locally advanced disease, or organ-preservation strategies for complete responders 1, 2, 6.